RxDoctor Payments Data

Ifeanyichukwu Ani, MD

Urology · Newport News, VANPI 1992967046

Payments from drug & device makers

$8,942in general payments, 2019–2025

Across 380 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Astellas Pharma US Inc$1K
  • AbbVie$1K
  • Pfizer$609
  • Sumitomo Pharma America, Inc.$609
  • Bayer$384
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$1,42016%
  • Food & beverage$7,32682%
  • Education$1952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,942 in reported general payments places this provider in the 70th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$316,068
Medicare patients
909
Services billed
4,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$269,555
MyrbetriqMirabegron69$58,227
Tolterodine Tartrate ErTolterodine Tartrate71$7,716
Tamsulosin Hcl239$2,953
Tadalafil14$2,366
Testosterone Cypionate53$2,226
NitrofurantoinNitrofurantoin Macrocrystal33$2,008
Finasteride155$1,968
Solifenacin Succinate33$1,641
Alfuzosin Hcl ErAlfuzosin Hcl137$1,552
Bicalutamide31$1,260
Desmopressin Acetate15$426
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$380
Trospium Chloride13$282
Levofloxacin133$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,232$327,78388 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 300 urology providers in Virginia.

Other urology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →